Oppenheimer Upgrades ResMed (RMD) to Outperform
Tweet Send to a Friend
Oppenheimer analyst Suraj Kalia upgraded ResMed (NYSE: RMD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
